These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 22570429)

  • 1. Risk of venous thromboembolism in patients with chronic liver disease and the utility of venous thromboembolism prophylaxis.
    Pincus KJ; Tata AL; Watson K
    Ann Pharmacother; 2012 Jun; 46(6):873-8. PubMed ID: 22570429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of pharmacologic prophylaxis for venous thromboembolism in patients with chronic liver disease.
    Barclay SM; Jeffres MN; Nguyen K; Nguyen T
    Pharmacotherapy; 2013 Apr; 33(4):375-82. PubMed ID: 23553808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Retrospective Cohort Analysis of Pharmacologic VTE Prophylaxis and Padua Prediction Score in Hospitalized Patients With Chronic Liver Disease.
    Moorehead KJ; Jeffres MN; Mueller SW
    J Pharm Pract; 2017 Feb; 30(1):58-63. PubMed ID: 26475125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for venous thromboembolism in patients with chronic liver disease.
    Walsh KA; Lewis DA; Clifford TM; Hundley JC; Gokun Y; Angulo P; Davis GA
    Ann Pharmacother; 2013 Mar; 47(3):333-9. PubMed ID: 23482730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary venous thromboembolism prophylaxis in ambulatory cancer patients.
    Aikens GB; Rivey MP; Hansen CJ
    Ann Pharmacother; 2013 Feb; 47(2):198-209. PubMed ID: 23386067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of hemorrhage in patients with chronic liver disease and coagulopathy receiving pharmacologic venous thromboembolism prophylaxis.
    Reichert JA; Hlavinka PF; Stolzfus JC
    Pharmacotherapy; 2014 Oct; 34(10):1043-9. PubMed ID: 25052037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
    Huo MH; Muntz J
    Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Warfarin for venous thromboembolism prophylaxis after elective hip or knee arthroplasty: exploring the evidence, guidelines, and challenges remaining.
    Dager WE
    Ann Pharmacother; 2012 Jan; 46(1):79-88. PubMed ID: 22202495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venous thromboembolism prophylaxis for medical service-mostly cancer-patients at hospital discharge.
    Fanikos J; Rao A; Seger AC; Piazza G; Catapane E; Chen X; Goldhaber SZ
    Am J Med; 2011 Dec; 124(12):1143-50. PubMed ID: 22114828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population.
    Reeves D; Liu CY
    J Oncol Pharm Pract; 2010 Mar; 16(1):27-31. PubMed ID: 19401307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of venous thromboembolism prophylaxis in patients with chronic liver disease.
    Smith CB; Hurdle AC; Kemp LO; Sands C; Twilla JD
    J Hosp Med; 2013 Oct; 8(10):569-73. PubMed ID: 24101541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature.
    Tufano A; Guida A; Di Minno MN; Prisco D; Cerbone AM; Di Minno G
    Semin Thromb Hemost; 2011 Apr; 37(3):267-74. PubMed ID: 21455860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.
    Vekeman F; LaMori JC; Laliberté F; Nutescu E; Duh MS; Bookhart BK; Schein J; Dea K; Olson WH; Lefebvre P
    J Med Econ; 2011; 14(3):324-34. PubMed ID: 21506632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and prevalence of venous thromboembolism in chronic liver disease: A systematic review and meta-analysis.
    Subhani M; Sheth A; Ahmed J; Wijayasiri P; Gardezi SA; Enki D; Morling JR; Aithal GP; Ryder SD; Aravinthan AD
    Thromb Res; 2022 Jul; 215():19-29. PubMed ID: 35594737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prophylaxis of venous thromboembolism].
    Hochauf S; Beyer J
    Hamostaseologie; 2008 Oct; 28(4):217-24. PubMed ID: 18836648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deep vein thrombosis prophylaxis in hospitalized medical patients: current recommendations, general rates of implementation, and initiatives for improvement.
    Stevens SM; Douketis JD
    Clin Chest Med; 2010 Dec; 31(4):675-89. PubMed ID: 21047575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rates of pharmacologic venous thromboembolism prophylaxis in hospitalized patients with active ulcerative colitis: results from a tertiary care center.
    Tinsley A; Naymagon S; Enomoto LM; Hollenbeak CS; Sands BE; Ullman TA
    J Crohns Colitis; 2013 Dec; 7(12):e635-40. PubMed ID: 23706933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Frequency of venous thromboembolism among hospitalized patients with cancer].
    Conte G; Figueroa G
    Rev Med Chil; 2008 Dec; 136(12):1528-34. PubMed ID: 19350169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venous thromboembolism risk and thromboprophylaxis among hospitalized patients: data from the Turkish arm of the ENDORSE study.
    Ongen G; Yılmaz A; Cirak AK; Ersoy CY; Erden F; Altıntaş F; Yıldırım C; Güven H; Demir A; Kaynar L; Bastacı N; Demirtaş N
    Clin Appl Thromb Hemost; 2011 Oct; 17(5):539-45. PubMed ID: 20829272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.